Big Molecule Watch
June 13, 2017

PTAB Finds Two Abbvie Adalimumab Method of Use Patents Unpatentable in Final Written Decisions

The PTAB has issued Final Written Decisions in IPRs filed by Coherus against two of Abbvie’s patents, IPR2016-00188 (U.S. Patent No. 9,017,680) and IPR2016-00189 (U.S. Patent No. 9.073,987), finding the challenged claims unpatentable as obvious over the prior art.  The patents are directed to methods of treating rheumatoid arthritis using adalimumab.  Adalimumab is marketed by Abbvie under the trade-name Humira®.

These decisions and other selected IPR documents regarding biologics are posted on our IPR tracker page.